Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Orell Mielke

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Trials|July 27, 2016
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trialIvo N van Schaik, Nan van Geloven, Vera Bril, et al.
Journal of the Peripheral Nervous System : JPNS|June 21, 2013
Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study)Jean-Marc Léger, Jan L De Bleecker, Claudia Sommer, et al.
Journal of the Peripheral Nervous System : JPNS|July 7, 2020
Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic reviewRichard A Lewis, David R Cornblath, Hans-Peter Hartung, et al.
Journal of the Peripheral Nervous System : JPNS|January 24, 2019
Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra studyOrell Mielke, Vera Bril, David R Cornblath, et al.
The Lancet. Neurology|November 11, 2017
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trialIvo N van Schaik, Vera Bril, Nan van Geloven, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|July 30, 2019
Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension studyIvo N van Schaik, Orell Mielke, Vera Bril, et al.
Frontiers in Neurology|April 3, 2025
Automatically quantified follow-up imaging biomarkers predict clinical outcomes after acute ischemic strokeSonya Abraham, Davide Carone, Orell Mielke, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 4, 2021
Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathyMichael A Tortorici, Theresa Yuraszeck, David Cornblath, et al.
Journal of the Peripheral Nervous System : JPNS|January 24, 2019
Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studiesIngemar S J Merkies, Ivo N van Schaik, Jean-Marc Léger, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Trials|July 27, 2016
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trialIvo N van Schaik, Nan van Geloven, Vera Bril, et al.
Journal of the Peripheral Nervous System : JPNS|June 21, 2013
Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study)Jean-Marc Léger, Jan L De Bleecker, Claudia Sommer, et al.
Journal of the Peripheral Nervous System : JPNS|July 7, 2020
Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic reviewRichard A Lewis, David R Cornblath, Hans-Peter Hartung, et al.
Journal of the Peripheral Nervous System : JPNS|January 24, 2019
Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra studyOrell Mielke, Vera Bril, David R Cornblath, et al.
The Lancet. Neurology|November 11, 2017
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trialIvo N van Schaik, Vera Bril, Nan van Geloven, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|July 30, 2019
Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension studyIvo N van Schaik, Orell Mielke, Vera Bril, et al.
Frontiers in Neurology|April 3, 2025
Automatically quantified follow-up imaging biomarkers predict clinical outcomes after acute ischemic strokeSonya Abraham, Davide Carone, Orell Mielke, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 4, 2021
Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathyMichael A Tortorici, Theresa Yuraszeck, David Cornblath, et al.
Journal of the Peripheral Nervous System : JPNS|January 24, 2019
Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studiesIngemar S J Merkies, Ivo N van Schaik, Jean-Marc Léger, et al.
Pageof 2